CATECHOL-O-METHYLTRANSFERASE INHIBITION BY U-0521 INCREASES STRIATAL UTILIZATION OF LEVODOPA

被引：20

作者：

RECHES, A

JIANG, D

FAHN, S

机构：

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1982年 / 320卷 / 01期

关键词：

D O I：

10.1007/BF00499068

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：34 / 37

页数：4

共 29 条

[1]

BARTHOLINI G, 1972, J PHARMACOL EXP THER, V183, P65

[2] 3-O-METHYLDOPA, A NEW PRECURSOR OF DOPAMINE [J].

BARTHOLINI, G ;

KURUMA, I ;

PLETSCHER, A .

NATURE, 1971, 230 (5295) :533-+

[3]

CALNE DB, 1972, CLIN PHARMACOL THER, V14, P386

[4]

CHASE TN, 1972, NEUROLOGY, V22, P417

[5] STRATEGIES FOR DETERMINATION OF SERUM OR PLASMA NOREPINEPHRINE BY REVERSE-PHASE LIQUID-CHROMATOGRAPHY [J].

DAVIS, GC ;

KISSINGER, PT ;

SHOUP, RE .

ANALYTICAL CHEMISTRY, 1981, 53 (02) :156-159

[6] POTENTIATION OF L-DOPA EFFECT IN MAN BY USE OF CATECHOL-O-METHYLTRANSFERASE INHIBITORS [J].

ERICSSON, AD .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1971, 14 (02) :193-&

[7] ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM - CLINICAL AND PHARMACOLOGIC CORRELATIONS AND EFFECT OF INTRAMUSCULAR PYRIDOXINE [J].

FAHN, S .

NEUROLOGY, 1974, 24 (05) :431-441

[8] EFFECT OF A CATECHOL-O-METHYL TRANSFERASE INHIBITOR, U-0521, WITH LEVODOPA ADMINISTRATION [J].

FAHN, S ;

COMI, R ;

SNIDER, SR ;

PRASAD, ALN .

BIOCHEMICAL PHARMACOLOGY, 1979, 28 (07) :1221-1225

[9]

FEUERSTEIN C, 1977, ACTA NEUROL SCAND, V56, P79

[10]

GILES RE, 1967, J PHARMACOL EXP THER, V156, P201

← 1 2 3 →